» Articles » PMID: 35263204

A Phase II Study of Obinutuzumab in Combination with Ibrutinib for Treatment of Relapsed Mantle Cell Lymphoma

Overview
Journal Leuk Lymphoma
Specialties Hematology
Oncology
Date 2022 Mar 9
PMID 35263204
Authors
Affiliations
Soon will be listed here.